Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-02-2016 | Review Article

Diagnostic accuracy of ¹⁸F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

Authors: Elizabeth Morris, Anastasia Chalkidou, Alexander Hammers, Janet Peacock, Jennifer Summers, Stephen Keevil

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2016

Abstract

Imaging or tissue biomarker evidence has been introduced into the core diagnostic pathway for Alzheimer’s disease (AD). PET using ¹⁸F-labelled beta-amyloid PET tracers has shown promise for the early diagnosis of AD. However, most studies included only small numbers of participants and no consensus has been reached as to which radiotracer has the highest diagnostic accuracy. First, we performed a systematic review of the literature published between 1990 and 2014 for studies exploring the diagnostic accuracy of florbetaben, florbetapir and flutemetamol in AD. The included studies were analysed using the QUADAS assessment of methodological quality. A meta-analysis of the sensitivity and specificity reported within each study was performed. Pooled values were calculated for each radiotracer and for visual or quantitative analysis by population included. The systematic review identified nine studies eligible for inclusion. There were limited variations in the methods between studies reporting the same radiotracer. The meta-analysis results showed that pooled sensitivity and specificity values were in general high for all tracers. This was confirmed by calculating likelihood ratios. A patient with a positive ratio is much more likely to have AD than a patient with a negative ratio, and vice versa. However, specificity was higher when only patients with AD were compared with healthy controls. This systematic review and meta-analysis found no marked differences in the diagnostic accuracy of the three beta-amyloid radiotracers. All tracers perform better when used to discriminate between patients with AD and healthy controls. The sensitivity and specificity for quantitative and visual analysis are comparable to those of other imaging or biomarker techniques used to diagnose AD. Further research is required to identify the combination of tests that provides the highest sensitivity and specificity, and to identify the most suitable position for the tracer in the clinical pathway.

Available only for authorised users

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.PubMedCrossRef

Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111cm33. doi:10.1126/scitranslmed.3002609.PubMedPubMedCentral

Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351:56–67.PubMedCrossRef

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–44.PubMedCrossRef

Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–53.PubMedCrossRef

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9. doi:10.1016/j.jalz.2011.03.005.

Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471–84.PubMedCrossRef

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19. doi:10.1002/ana.20009.PubMedCrossRef

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.PubMedCrossRef

10.

Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557–68.PubMedPubMedCentralCrossRef

11.

Hatashita S, Yamasaki H. Clinically different stages of Alzheimer’s disease associated by amyloid deposition with 11C-PIB PET imaging. J Alzheimers Dis. 2010;21:995–1003. doi:10.3233/JAD-2010-100222.PubMed

12.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131:1630–45. doi:10.1093/brain/awn016.PubMedPubMedCentralCrossRef

13.

Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431–4. doi:10.1001/archneur.64.3.431.PubMedCrossRef

14.

Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med. 2014;41:290–300.CrossRef

15.

European Medicines Agency. Amyvid: florbetapir (18F). Authorisation details. 1999. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002422/human_med_001611.jsp&mid=WC0b01ac058001d124. Accessed 22 Oct 2015.

16.

European Medicines Agency. Neuraceq: florbetaben (18F). Authorisation details. 1999. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002553/human_med_001716.jsp&mid=WC0b01ac058001d124. Accessed 22 Oct 2015.

17.

European Medicines Agency. Vizamyl: flutemetamol (18F). Authorisation details. 1999. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002557/human_med_001794.jsp&mid=WC0b01ac058001d124. Accessed 22 Oct 2015.

18.

Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.PubMedCrossRef

19.

Camus V, Payoux P, Barre L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med. 2012;39:621–31.CrossRef

20.

Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.PubMedCrossRef

21.

Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, et al. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer’s disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One. 2013;8;e58974.PubMedPubMedCentralCrossRef

22.

Newberg AB, Arnold SE, Wintering N, Rovner BW, Alavi A. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med. 2012;53:902–7.PubMedCrossRef

23.

Siderowf A, Pontecorvo M, Shill H, Mintun M, Arora A, Joshi A, et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders. BMC Neurol. 2014;14:79.PubMedPubMedCentralCrossRef

24.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.PubMedCrossRef

25.

Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.PubMedCrossRef

26.

Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedPubMedCentralCrossRef

27.

Whiting P, Weswood M, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9.PubMedPubMedCentralCrossRef

28.

Leeflang MM, Deeks JJ, Takwoingi Y, Macaskill P. Cochrane diagnostic test accuracy reviews. Syst Rev. 2013;2:82.PubMedPubMedCentralCrossRef

29.

Chalkidou A, Landau DB, Odell EW, Cornelius VR, O'Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499–513. doi:10.1016/j.ejca.2012.05.001.PubMedCrossRef

30.

Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM; Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97. doi:10.7326/0003-4819-149-12-200812160-00008.PubMedPubMedCentralCrossRef

31.

Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol. 2005;5:19.PubMedPubMedCentralCrossRef

32.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700.PubMedPubMedCentralCrossRef

33.

Raniga P, Bourgeat P, Fripp J, Acosta O, Villemagne VL, Rowe C, et al. Automated 11C-PiB standardized uptake value ratio. Acad Radiol. 2008;15:1376–89. doi:10.1016/j.acra.2008.07.006.PubMedCrossRef

34.

Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309:188.PubMedPubMedCentralCrossRef

35.

Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–35.PubMedCrossRef

36.

Ikari Y, Nishio T, Makishi Y, Miya Y, Ito K, Koeppe RA, et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI) multi-center study. Ann Nucl Med. 2012;26:535–44. doi:10.1007/s12149-012-0605-4.PubMedCrossRef

37.

Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.PubMed

38.

Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. Am J Neuroradiol. 2013;34:944–50, S1–S11. doi:10.3174/ajnr.A3324.

39.

Richards D, Sabbagh MN. Florbetaben for PET imaging of beta-amyloid plaques in the brain. Neurol Ther. 2014;3:79–88.PubMedPubMedCentralCrossRef

40.

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050–68.PubMedCrossRef

41.

Heckemann RA, Hajnal JV, Aljabar P, Rueckert D, Hammers A. Automatic anatomical brain MRI segmentation combining label propagation and decision fusion. Neuroimage. 2006;33:115–26. doi:10.1016/j.neuroimage.2006.05.061.PubMedCrossRef

42.

Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, et al. [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54:347–57. doi:10.1016/j.neuint.2008.12.016.PubMedCrossRef

43.

Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, et al. 11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;7:CD010386. doi:10.1002/14651858.CD010386.pub2.PubMed

44.

Mitchell AJ. A meta-analysis of the accuracy of the Mini-Mental State Examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009;43:411–31. doi:10.1016/j.jpsychires.2008.04.014.PubMedCrossRef

45.

Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011;26:627–45.PubMedCrossRef

46.

Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–46.PubMedCrossRef

47.

Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19:1487–501. doi:10.1111/j.1468-1331.2012.03859.x.CrossRef

48.

Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013;54:476–90.PubMedCrossRef

Title: Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis
Authors: Elizabeth Morris
Anastasia Chalkidou
Alexander Hammers
Janet Peacock
Jennifer Summers
Stephen Keevil
Publication date: 01-02-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3228-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Diagnostic accuracy of ¹⁸F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

A “new/old method” for TSH stimulation: could a third way to prepare DTC patients for 131I remnant ablation possibly exist?

Thoracic fat volume is independently associated with coronary vasomotion

Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality

Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis

The prognostic value of baseline 18F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters

PET/MRI and PET/CT: is there room for both at the top of the food chain?